Nephron Research Liquid Biopsy Symposium – June 16th, 2021

Liquid biopsy represents a significant, untapped market for our coverage. Advances in science are opening several new clinical applications for genomics across cancer screening, minimal residual disease (MRD) testing and comprehensive genomic profiling (CGP). There is a very wide range of outcomes – with the potential to transform healthcare diagnosis and treatment in a bull case, and clinical & commercial risks in the downside case.

Nephron Research’s Liquid Biopsy Symposium will help investors digest the big debates which will influence the size of the market opportunity for liquid biopsy in the coming years.  In June 16th, we will bring together a diverse set of opinions from the leading innovators across public and private companies, as well as the top industry experts on the key debates around clinical data, reimbursement and regulatory pathways to commercialization.

Participating companies include: Exact Sciences (EXAS), Guardant Health (GH), Natera (NTRA), Biological Dynamics (Private), and more.

Expert panels will focus on the top debates related to clinical data, reimbursement and regulation. for more info.